P. Stahle

CHARACTERIZATION OF RWJ‐351647, A NOVEL NONPEPTIDE VASOPRESSIN V2 RECEPTOR ANTAGONIST

B. Maryanoff, B. Damiano, L. de Garavilla, 2006, Clinical and experimental pharmacology & physiology.

Chlorpromazine-sensitive developmental processes in the sea urchin, Lytechinus pictus. I: Inhibition of cleavage, gastrulation and primary mesenchyme cell differentiation

K. Anitole, K. M. Brown, N. Lappas, 1988 .

Development of lipophilic anticancer agents for the treatment of brain tumors by the esterification of water-soluble chlorambucil

N. Greig, S. Rapoport, I. Lieberburg, 1993, Clinical & Experimental Metastasis.

Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat

N. Greig, U. Shetty, J. Deutsch, 2004, Cancer Chemotherapy and Pharmacology.

Preclinical safety assessment of JNJ-10450232 (NTM-006), a structural analog of acetaminophen, that does not cause hepatotoxicity at supratherapeutic doses.

E. Kuffner, D. Gallacher, C. M. Flores, 2023, Regulatory toxicology and pharmacology : RTP.

The Novel, Orally Active, Delta Opioid RWJ-394674 Is Biotransformed to the Potent Mu Opioid RWJ-413216

P. Pitis, W. Wu, R. Colburn, 2006, Journal of Pharmacology and Experimental Therapeutics.